Bills · HR 2450
IN COMMITTEE· 119TH CONGRESS
House BillHR 2450Health
Prescription Drug Transparency and Affordability Act
INTRO MAR 27· LAST ACTION MAR 27
READING
63MIN
COSPONSORS
3BIPARTISAN
READER REACTIONS0 TOTAL
NO VOTES YET · BE THE FIRST
- Introduced only
LEGISLATIVE PROGRESS
STEP 2 / 8Introduced
In Committee
Reported
Passed House
Passed Senate
Conference
To President
Became Law
WHAT THE BILL DOES
AI-writtenThis bill matters because prescription drug costs are a major concern for many Americans, and the current system of pricing is often complex and opaque. Many people don't understand why their medications cost what they do, and health plans struggle to see the full picture of how money flows between drug manufacturers, PBMs, and pharmacies. This bill seeks to pull back the curtain on these financial dealings, particularly the role of PBMs as intermediaries.
If this bill becomes law, health plans would gain unprecedented access to specific, drug-level pricing and rebate information. This new transparency could allow them to negotiate better deals, identify inefficiencies, and challenge questionable pricing practices. Without this law, the current lack of detailed financial reporting would continue, making it harder for health plans to control costs and for consumers to understand the true drivers of their prescription drug expenses. Ultimately, it could lead to more competitive drug pricing and potentially more affordable medications for consumers.
KEY PROVISIONS
5AI-extractedPROVISION 01
PBMs are prohibited from limiting or delaying the disclosure of specific drug pricing information to group health plans.
This ensures health plans have the necessary data to understand drug costs and PBM compensation.
PROVISION 02
PBMs must submit detailed reports to group health plans at least every six months (or quarterly if requested).
This creates a regular, mandatory flow of critical financial information that plans currently may not receive.
PROVISION 03
Reports must include compensation paid by the plan to the PBM for each drug and the compensation paid by the PBM to the pharmacy for each drug, showing the difference.
This reveals the profit margins PBMs make on individual drugs, an area often criticized for its lack of transparency.
PROVISION 04
Reports must detail rebates, fees, discounts, and other payments received by both the health plan and the PBM from drug manufacturers and other entities.
This clarifies how much PBMs keep from rebates, which is a significant factor in overall drug costs.
PROVISION 05
Reports must include information on drug dispensing channels (retail, mail order, specialty), whether drugs are brand or generic, wholesale acquisition cost/average wholesale price, and total patient out-of-pocket spending.
This provides a comprehensive view of drug utilization, costs, and patient financial burden, allowing for more informed decision-making.
SPONSORSHIP
1 + 3
D· Michigan
YRS IN OFFICE
1
BILLS LED
19
COSPONSOR BREAKDOWNBIPARTISAN · 66%
DEM 1 REP 2 IND 0
ACTION TIMELINE
2 EVENTSMAR 27
Introduced in House
MAR 27
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
BILL INFO
TypeHouse Bill
NumberHR 2450
Congress119th
StatusIn Committee
IntroducedMar 27, 2025
Last actionMar 27, 2025
READER REACTIONS
OVERALL SENTIMENT
No reactions yet. Be the first to weigh in.
Discussion
Loading comments...
IN COMMITTEE· 119TH CONGRESS · WAYS AND MEANS COMMITTEE · INTRODUCED MAR 27, 2025
House BillHR 2450Health
Prescription Drug Transparency and Affordability Act
INTRODUCED MAR 27, 2025· LAST ACTION MAR 27, 2025
PASSAGE CHANCES
—%
READING
63 min
COSPONSORS
3
COMPLEXITY
Moderate
